Triazavirin sodium hydrate (TZV, Riamilovir)

Description :Triazavirin sodium hydrate (TZV, Riamilovir), a nucleoside analogue of nucleic acid, is a broad-spectrum and potent antiviral agent. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, 6 and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2. Triazavirin works by inhibiting the synthesis of viral RNA and DNA and replication of genomic fragments. Triazavirin is also an effective protective agent on the transmission stage of influenza.

References:

1. Kozhikhova KV, et al. Preparation of chitosan-coated liposomes as anovel carrier system for the antiviral drug Triazavirin. Pharm DevTechnol. 2018 Apr; 23(4):334-342.

2. LoginovaSIa, et al. Investigation of Triazavirin antiviral activity againsttick-borne encephalitis pathogen in cell culture. Antibiot Khimioter.2014; 59(1-2):3-5.

3. LoginovaSY, et al. Investigation of Therapeutic Efficacy of Triazavirin AgainstExperimental Forest-Spring Encephalitis on Albino Mice. AntibiotKhimioter. 2015; 60(7-8):11-3.